[Ip-health] OECD background paper on excessive pricing in pharmaceuticals

Suerie Moon suerie.moon at graduateinstitute.ch
Thu Oct 25 06:36:10 PDT 2018


Dear ip-health readers,

OECD's Competition Committee Secretariat released this background paper on
excessive pricing in the pharmaceutical market in early October:
http://www.oecd.org/officialdocuments/publicdisplaydocumentpdf/?cote=DAF/COMP(2018)12&docLanguage=En

Overall they seem to take a rather cautious approach to using competition
law as a tool to control prices, but do see some areas for potential use.

For those who are interested in the topic -- Prof Fred Abbott gave a very
interesting presentation on competition law and excessive pricing at the
recent Global Congress on IP and the Public Interest in Washington DC, and
his work is cited in the OECD report.

I am no expert on competition law, and would be interested in hearing the
views of this report from others who have looked more closely at the
topic.

Best wishes,
Suerie
______________________________________________________________________________
Suerie Moon, MPA, PhD
Director of Research, Global Health Centre and Visiting Lecturer, Graduate
Institute of Geneva
Adjunct Lecturer, Dept. of Global Health and Population, Harvard T.H. Chan
School of Public Health
Bureau P2-712, Maison de la Paix, Chemin Eugène-Rigot 2, CP 1176, 1211
Geneva, Switzerland
Tel: +41-22-908-5845       Mobile: +41-76-823-2830           Skype ID:
sueriemoon


More information about the Ip-health mailing list